We are live on ! Find out more
LYEL icon

Lyell Immunopharma

52 hedge funds and large institutions have $1.29B invested in Lyell Immunopharma in 2021 Q2 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.64% more ownership

Funds ownership: 0%1.64% (+1.6%)

Holders
52
Holders Change
+52
Holders Change %
% of All Funds
0.9%
Holding in Top 10
8
Holding in Top 10 Change
+8
Holding in Top 10 Change %
% of All Funds
0.14%
New
52
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

LYEL Hedge Fund Activity: Q2 2021 in Review

52 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q2 2021, worth a combined $1.29B.

Buyers outnumbered sellers: 52 funds opened new LYEL positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was MWG Management, opening a new position worth an estimated $333M.

  • 52 institutional investors held Lyell Immunopharma (LYEL) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $1.29B of Lyell Immunopharma stock for Q2 2021.
  • 52 funds opened new Lyell Immunopharma positions in Q2 2021 and 0 closed out, a net change of +52 holders.
  • The largest Lyell Immunopharma buyer in Q2 2021 was MWG Management, an estimated $333M added.

Based on aggregated 13F filings for Q2 2021.